Mechanism of Astragaloside IV in Treatment of Renal Tubulointerstitial Fibrosis.
10.1007/s11655-024-3805-6
- Author:
Xin-Ru WANG
1
;
Jing-Xiang LUAN
1
;
Zhao-An GUO
2
,
3
Author Information
1. First Clinical Medical College, Shandong University of Traditional Chinese Medicine, Jinan, 250014, China.
2. Department of Nephrology, Affiliated Hospital of Shandong University of Traditional Chinese Medicine, Jinan, 250014, China. gza63@
3. com.
- Publication Type:Review
- Keywords:
Chinese medicine;
astragaloside IV;
autophagy;
endoplasmic reticulum stress;
macrophages;
review;
tubulointerstitial fibrosis
- MeSH:
Saponins/pharmacology*;
Triterpenes/pharmacology*;
Humans;
Fibrosis;
Animals;
Kidney Tubules/drug effects*;
Kidney Diseases/pathology*
- From:
Chinese journal of integrative medicine
2025;31(5):474-480
- CountryChina
- Language:English
-
Abstract:
Tubulointerstitial fibrosis (TIF) is one of the key indicators in evaluating the renal function of patients. Mild TIF can cause a vicious cycle of renal tubular glomerular injury and aggravate renal disease. Therefore, studying the mechanisms underlying TIF is essential to identify therapeutic targets, thereby protecting the renal function of patients with timely intervention. Astragaloside IV (AS-IV) is a Chinese medicine component that has been shown to inhibit the occurrence and progression of TIF via multiple pathways. Previous studies have reported that AS-IV protected against TIF by inhibiting inflammation, autophagy, endoplasmic reticulum stress, macrophages, and transforming growth factor-β1, which laid the foundation for the development of a new preventive and therapeutic option for TIF.
